PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 5, 2026Journal of Pediatric Endocrinology and Diabetes0 citationsOpen Access

Resistance to thyroid hormone alpha (RTHα) due to a de novo THRA p.Asp268Asn variant: Early levothyroxine treatment and outcome

CWCatherine Tsz Wai WongJCJasmine Chow

Key Points

  • To explore the outcomes of early levothyroxine treatment in a child with a de novo THRA variant causing RTHα.
  • Case report of a 12-year-old with a de novo THRA variant (c.802G>A, p.Asp268Asn)
  • Initiated levothyroxine treatment at 14 months
  • Monitored energy levels, motor skills, and school performance over time.
  • Improvement in energy and motor milestones after treatment.
  • Enhanced school performance noted during follow-up.
  • Highlights the need for early thyroid function assessment and genetic testing in similar cases.

Abstract

Resistance to thyroid hormone alpha (RTHα) is a rare disorder that may present with clear hypothyroid features despite normal thyroid-stimulating hormone (TSH) and marginally low free thyroxine (FT4), leading to underrecognition. We report a 12-year-old with a de novo thyroid hormone receptor alpha ( THRA ) variant (c.802G>A, p.Asp268Asn), treated with levothyroxine from the age of 14 months, who showed improved energy, motor milestones, and school performance. This case highlights that children with disproportionate hypothyroid signs and subtle thyroid function test abnormalities warrant early assessment of free triiodothyronine (FT3), timely THRA genetic testing, and a monitored levothyroxine trial, which may benefit milder RTHα phenotypes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wong et al. (2026) studied this question.

synapsesocial.com/papers/6a2268f9763171746d5477f1https://doi.org/10.25259/jped_24_2026
Ask AI
Helpful
Bookmark
Share
View Full Paper